Research-Focused and determined to find a cure
Improving Health Outcomes
As the largest nonproﬁt funder of psoriatic disease research in the world, NPF’s investment strategy focuses on drug development and other approaches to improve health outcomes for everyone with psoriatic disease. We have invested over $19 million so far.
The road to better treatments begins with basic research that answers fundamental questions about disease mechanisms. At this early stage, scientists need critical support to test their promising ideas. NPF’s Discovery Grants advance basic science research
Bridging the gap between the laboratory and daily life, translational researchers do the costly and time-consuming work of converting discoveries from basic research into treatments that can be tested in clinical trials. NPF supports translational research through our Translational Research Grants program.
Clinical research is the phase of drug development when treatments are tested in patients to measure their clinical effects. Many NPF fellowship recipients work on clinical trials with the aim of bringing new drugs to market, or finding new uses for drugs that are already available.
MEETINGS + PROGRAMS
The Symposium serves as a way to jump-start the careers of the next generation of clinicians and scientists pursuing psoriatic disease research. Over the two-day event, recent graduates have an opportunity to share their work, network with peers and get indispensable guidance from leading researchers.
There’s a simple idea behind Citizen Pscientist Give non-scientists the chance to play with science. Let the people who live with psoriatic disease contribute their data, work with the data, discuss what they find and give researchers new leads. The more leads researchers have, the greater their chances of discovering a cure.
The Psoriatic Disease Research Ambassadors (PDRA) are a nationwide group of specifically trained psoriatic disease patients who will help advance NPF’s patient-centered research initiatives. Research Ambassadors (RAs) receive special training and education and provide ongoing guidance for patient-centered research.
The 2019 Future of Psoriatic Disease Symposium will inaugurate a new NPF effort to develop a scientific roadmap to achieve prevention, precision medicine and a cure for psoriatic diseases.
The National Psoriasis Victor Henschel BioBank is a collection of biological samples and clinical information used by qualified scientists to advance the field of psoriatic disease genetics. Established in 2006, it is one of the largest collections of psoriatic disease DNA samples in the United States.
From our Advance Online Blog
The best treatment starts with a team of medical professionals who are up-to-date with today’s care options.
NPF board of directors member Richard Seiden shares his notes.